替罗非班氯化钠治疗急性冠脉综合症的安全性探讨

To Eoplore the Safety of Hydrochloride Tirofiban Sodium in Treating Acute coronary Syndromes

目的:探讨盐酸替罗非班氯化钠治疗急性冠脉综合症患者的临床疗效及安全性。方法:急性冠脉综合症患者46例,分治疗组18例,对照组28例。对照组以阿司匹林0.3嚼碎顿服,低分子肝素(立迈青针)5000u,腹壁皮下注射12h1次,共10d,阿司匹林0.1晨服,波立维75mg晨服,及应用辛伐他汀、倍他乐克、卡托普利、硝酸甘油等治疗;治疗组在此基础上应用盐酸替罗非班氯化钠注射液,前30m in以0.4ug/Kg/m in负荷输入,后以0.1ug/Kg/m in静脉泵输入维持24h;观察两组疗效。结果:总有效率治疗组与对照组比较无显著性差异(P>0.05),冠状动脉造影结果显示联合治疗组病变血管血栓减少,临床疗效明显。治疗组与对照组不良反应无显著性差异(P>0.05)。结论:在低分子肝素基础上加用替罗非班治疗急性冠脉综合症,不增加严重出血的发生,安全性较好。

Objective： To explore the safety of hydrochloride tirofiban sodium in treating acute coronary syndromes. Method： 46 cases acute coronary syndrome （ACS） were divided into treatment group （18 cases） and control group （28 cases）. The cases in control group were given 0.3g aspirin for chawing, 5000u low molecular weight haperins were injected abdominally once for 12 hours total for 10 days one course. In the morning they took 0.1 g aspirin and 75rag clopidogrel bisulfate, in the mean while, simvastatin betaloc, captopril and nitroglycerin were used. While the cases in treatment group were pumped intravenous of 0. 4μg/kg. rain hydrochloride tirofiban sodium at the first 30 minutes, then as 01μg/kg. min for 24 hours on the basis treatment of the control group. Then observed the effect of both groups. Result： There＇s no significant difference bftotal effective rate between two groups （ P 〉 0.05 ） while the thrombosis were decreased clinically in treatment group. There＇s no significant difference of side reaction in both groups （ P 〉 0.05 ）. Conclusion： It＇s safe to treat acute ACS with hydrochloride tirofiban sodium on the basis of low molecular weight haerins. There＇s no tendency to increase the hemorrhage.